During
regular
trading
hours,
there
were
many
stocks
that
continued
to
break
up
to
the
upside.
These
stocks
are
usually
going
up
with
news.If
you
are
looking
to
day
trade
also
check
out
my
Top 2011 Stock Gainers, Stocks to Buy 2012.My Daily Trading Activities - Membership Link
Quick Look Market Closing Price:
Treasurys: 30-year -0.07%. 10-yr -0.01%. 5-yr +0.01%.
Commodities: Crude -0.79% to $91.75. Gold -0.34% to $1777.15.
Currencies: Euro +0.23% vs. dollar. Yen +0.17%. Pound -0.04%
After Hours News:
InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its Esbriet pulmonary fibrosis drug - the company expects sales to begin on Jan. 1. Esbriet has already been approved for use in Japan, South Korea, and 29 European countries, but FDA approval is still pending the outcome of clinical trials.
InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its Esbriet pulmonary fibrosis drug - the company expects sales to begin on Jan. 1. Esbriet has already been approved for use in Japan, South Korea, and 29 European countries, but FDA approval is still pending the outcome of clinical trials.
Xyratex (XRTX): FQ3 EPS of $0.37 misses by $0.07. Revenue of $275.7M (-24% Y/Y) misses by $43M. Xyratex's FQ3: Revenue was in-line with the guidance Xyratex provided in its September warning. But FQ4 revenue is expected to be within a range of $235M-$285M and EPS of -$0.15 to -$0.43, well below an outdated consensus of $327.9M and $0.49. In addition to noting the qualification delays partly behind its FQ3 warning, Xyratex claims "industry dynamics are weaker than what was expected a few months ago" - possibly bad news for customers NTAP, STX, and WDC. XRTX -11.5% AH
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com
